Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
Original ArticleCharacterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
Introduction
Preeclampsia is a serious complication of pregnancy where the anti-angiogenic factors sFlt-1 and soluble endoglin (sEng) are released from the placenta into the maternal circulation. Together these factors inflict widespread endothelial dysfunction, ultimately necessitating delivery of the baby and placenta [1], [2]. They are perhaps the most studied molecules in the field of preeclampsia. Although they were identified almost a decade ago [3], [4], our understanding of the molecular mechanisms regulating their release from the placenta is still limited. Furthermore, identifying potential drugs that can decrease release of these factors from primary placental cells could be a strategy to discover candidate therapeutics for preeclampsia. For these reasons, a robust trophoblast cell system that can be used to undertake functional experiments examining the production and release of sFlt-1 and sEng is important to develop.
Choriocarcinoma derived cells and immortalized trophoblast cells (e.g. BeWos, JAR or JEG3 cells) are commonly used to functionally examine placental biology, including by us [5], [6], [7], [8], [9]. However, while convenient to use, there are concerns arising from the fact they are immortalized and may not reflect true trophoblast biology. Furthermore, we have screened commonly used trophoblast cells and found they secrete low or undetectable levels of sFlt-1 and sEng (see Table 1). As such, they are perhaps particularly unhelpful to functionally interrogate the mechanisms of sFlt-1 and sEng production in placenta.
Primary placental explants are another alternative. They have the advantage of being primary tissue and therefore better reflect trophoblast biology than cell lines. However, they are highly challenging to functionally manipulate. While protocols to transfect siRNAs into primary explants have been published, we have not been able to consistently obtain gene silencing efficiencies following these protocols [10]. Furthermore, we have found sflt-1 and sEng secretion between different placental explants can be extremely variable, making results difficult to interpret.
As such, studying the molecular regulation of sFlt-1 and sEng in the placenta might be best done using primary trophoblast cells. These cells should produce both factors and be amenable to siRNA gene silencing. Surprisingly, there has been very little primary trophoblast based functional interrogation of sflt-1 and sEng production. Most cell studies of sFlt-1 and sEng production have used human umbilical vein endothelial cells (HUVECs), cell lines [6], [11], [12], [13], [14] or placental explants.
Therefore, we set out to characterize a specific protocol for isolating primary term trophoblast cells, optimized for functional interrogation of the anti-angiogenic factors sFlt-1 and sEng. Specifically, we report the levels of sFlt-1 and sEng production and examine the effects of length of time in culture, forskolin and hypoxia. We also set out to confirm genes can be readily silenced using the protocol we describe and to demonstrate the protocol we have developed provides primary trophoblast cells that are readily amenable for functional studies.
Furthermore, while protocols of trophoblast isolation have been previously published [15], [16], [17], [18], [19], there are some important issues that have not been specifically examined. For instance, some investigators have dispensed with further purification from contaminating fibroblasts after percoll gradient separation, raising the question whether the negative selection step does yield significantly more pure populations, or can be dispensed with. Secondly, given the trophoblast cells spontaneously syncytialize, it is not clear whether adding forskolin significantly enhances syncytialization further, or is unnecessary. Therefore, in this technical report, we also set out to specifically resolve these questions. We examined the secretion of hCG, sFlt1 and sEng in cells before and after CD9 negative selection (the purification step), and also assessed the effects of adding forskolin.
Section snippets
Tissue collection
Women presenting to the Mercy Hospital for women gave informed written consent for placental tissue collection. Placentas were obtained from normal term pregnancies at caesarian section. Tissue was collected within 30 min of delivery for isolation of primary trophoblasts.
Primary trophoblast isolation
Approximately 150 g of placental tissue was washed thoroughly in ice-cold phosphate buffered saline (PBS) before both the maternal and fetal surfaces were dissected away and discarded. Placental cotyledons were scraped with a
sFlt-1 and sEng production by commonly utilized trophoblast cell lines
We measured levels of sFlt-1 and sEng in the media obtained from the following trophoblast cell lines: JAR, AC1M188, AC1M32, HTR8, JEG-3 and BeWo cells (Table 1). sEng was produced by JAR, JEG-3 and BeWo cells and only the immortalized HTR8 cells produced measurable levels of sFlt-1. Significantly, none produced both sFlt-1 and sEng. Thus, none of the commonly used trophoblast cell lines appear well suited to examine the molecular biology regulating both sFlt-1 and sEng production.
CD9 negative selection produces a pure trophoblast population
As discussed,
Discussion
In this study we present a specific protocol for primary trophoblast isolation and purification optimized for the functional investigation of sFlt-1 and sEng. We have shown this protocol can be used to isolate a pure population of trophoblast cells of high purity utilizing percoll gradient separation and CD9 negative selection. Interestingly, we have demonstrated differential production of sEng and hCG (but unchanged sFlt1 levels) in cells obtained after CD9 negative selection. At a functional
Ethics Statement
Human Ethics approval was obtained for this study from the Mercy Health Human Research Ethics Committee.
Sources of funding
The National Health and Medical Research Council of Australia provided salary (#1062418 to T.K, #628927 to N.H, #1050765 to S.T.) and Australian Postgraduate Award to F.B.
Disclosure statement
The authors have nothing to disclose.
Competing interest
The authors have declared that no competing interests exist.
Acknowledgements
The authors acknowledge Clinical Research midwives Gabrielle Pell, Debra Jinks, Rachel Murdoch and Genevieve Christophers and the Obstetrics midwifery staff and patients at the Mercy Hospital for Women (Heidelberg) for their provision of placental tissue.
References (21)
- et al.
MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin
Am J Pathol
(2012) - et al.
MT-MMPs in pre-eclamptic placenta: relationship to soluble endoglin production
Placenta
(2013) - et al.
PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia
Placenta
(2013) - et al.
Methods for siRNA-mediated reduction of mRNA and protein expression in human placental explants, isolated primary cells and cell lines
Placenta
(2009) - et al.
In vitro cultured human term cytotrophoblast: a model for normal primary epithelial cells demonstrating a spontaneous differentiation programme that requires EGF for extensive development of syncytium
Placenta
(1997) - et al.
Heme oxygenase-1 in placental development and pathology
Placenta
(2013) - et al.
Placental and trophoblastic in vitro models to study preventive and therapeutic agents for preeclampsia
Placenta
(2011) - et al.
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease
Circulation
(2011) - Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet...
- et al.
Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia
J Clin Invest
(2003)
Cited by (53)
Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
2022, Pregnancy HypertensionRenin-angiotensin system (RAS) enzymes and placental trophoblast syncytialisation
2022, Molecular and Cellular EndocrinologyPlacental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling
2021, PlacentaCitation Excerpt :Equal amounts of protein were loaded to measure PlGF via ELISA. Primary cytotrophoblast cells were isolated as previously described from women undergoing elective caesarean section at term [11]. Placentas were collected within 30 min of delivery as described above.